HIV-specialist company ViiV Healthcare, majority owned by UK pharma major GlaxoSmithKline (LSE: GSK), is facing opposition in India to two patent applications it has submitted for dolutegravir (trade name Tivicay) and cabotegravir...The protestors claim that by securing the patents, ViiV Healthcare would block open generic competition among Indian producers and prevent thousands of patients from accessing life-saving medicine...a spokesperson for Viiv Healthcare said: "We believe that our access to medicines strategy addresses the needs of people living with HIV in India. In 2013 we signed separate agreements with the Medicines Patent Pool (MPP) and Aurobindo to ensure access to our innovative antiretroviral medicines and combinations, including dolutegravir, where the need is greatest.